Skip to Main Content
Try STAT+ TODAY
Trending:
Pharmalot
Coronavirus
Health
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Adam's Take
STAT+

Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals

  • Adam Feuerstein

By Adam Feuerstein April 13, 2020

Reprints
Biotech in the time of corona
Mike Reddy/STAT

Seeing the Easter Bunny wear a mask was weird. Greetings and welcome to another semi-regular column on the Covid-19 pandemic. In this edition: When will biotech M&A return? Did Sage Therapeutics CEO take a pay cut? Biotech in an America First world; and more chatter about #JPM21.

What will it take for mergers and acquisitions to return to biotech?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

Trending
In a doctor’s suspicion after a miscarriage, a glimpse…
In a doctor’s suspicion after a miscarriage, a glimpse of expanding medical mistrust
contraception abortion
Supreme Court decision suggests the legal right to contraception…
Supreme Court decision suggests the legal right to contraception is also under threat
Comparing the Pfizer and Moderna Covid vaccines for young…
Comparing the Pfizer and Moderna Covid vaccines for young children
Recommended
Dollars
‘A slippery slope’: Pfizer sells a contraceptive and donated…
‘A slippery slope’: Pfizer sells a contraceptive and donated to political groups that could come after…
Pharmalot Coming/Going STILL
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: Senate Dems vet a tweaked version of drug-pricing…
Pharmalittle: Senate Dems vet a tweaked version of drug-pricing bill; biotechs double down on developing birth…

Recommended Stories

Adam's take main illustration
Adam's Take

Not-so-happy midyear! Biotech CEOs, best and worst, and a hopeful sign of a turnaround

By Adam Feuerstein

Vascepa pill handout
Biotech

New analysis of Amarin’s Vascepa resurrects big questions about effectiveness

By Matthew Herper

Descovy Truvada patient assistance program
Pharmalot

A ‘colossal financial fraud’: Gilead to get $33 million from a clinic for exploiting its HIV patient assistance program

By Ed Silverman

Cue Health overgrowth illustration
A STAT Investigation

Cue Health rode Covid-19 to an NBA deal and a $3 billion valuation. Now it faces layoffs and a rocky future

By Katie Palmer

CVS Pharmacy
Pharmalot

A CVS whistleblower lawsuit comes at a pivotal moment for the FTC’s probe of pharma and PBMs

By Ed Silverman